Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

nt.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: our ability to enroll approximately six patients at the 600mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter of 2008; Cadence's ability to enroll sufficient patients to complete the Omigard CLIRS trial; the adequacy of the CLIRS trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard; Cutanea's ability to manage, fund and advance omiganan for dermatological applications into Phase III, the adequacy of Cutanea's Phase II results for regulatory authorities to support advancing to Phase III; our ability to manage licensing opportunities; and our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on corporate collaborations; potential delays; uncertainties related to early stage of technology and product development; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our products; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns; the possibility that opportunities will arise that require more cash than presently anticipated and other uncertainties related to predictions of future cash requirements; and other risks and uncertainties which may not
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Our ... acknowledgement is a national disgrace. Furthermore, every governmental ... establishing the current, deplorable state of unorganized dysfunction ... great mistakes," to merely serve as a device ... extent of colossal failure(s) that have accumulated through ...
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... The College of New Rochelle announced today ... Mid-Hudson Region to be designated as a START-UP NY ... qualified “high-technology” businesses that align with the College’s academic ... been selected for the START-UP NY program and extremely ... economic development in New York by growing business and ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... of assay of cell-mediated ... immunity, ... data on the monitoring of cell-mediated immunity (CMI) in adult patients,undergoing heart ... demonstrated that ImmuKnow(R) values,appear to closely reflect the immune function of the ...
... REHOVOT, Israel and JERSEY CITY, New Jersey, April ... leader in,the development of microRNA-based diagnostics and therapeutics, ... upcoming annual AACR,conference in San Diego. The posters ... and how they may be applied to develop,objective ...
... Zentaris Inc.,(Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical ... that David J. Mazzo, Ph.D.,has resigned as President ... the,Board of Directors of AEterna Zentaris, effective immediately. ... of AEterna Zentaris, has been,appointed as the interim ...
Cached Biology Technology:Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 2Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5AEterna Zentaris Announces Changes to its Management Team 2
(Date:8/22/2014)... reductase (DHCR24) is a multifunctional enzyme ... and has neuroprotective and cholesterol-synthesizing activities. ... caused by amyloid β deposition. Dr. ... University in China constructed two recombinant ... DHCR24 expression specifically in neuronal cells. ...
(Date:8/21/2014)... in past decade, GTA still violates Canada,s ozone ... the Greater Toronto Area (GTA) has significantly reduced ... the city continues to violate the Canada-wide standards ... or aggravate health problems such as asthma, emphysema ... of complex photochemical reactions involving volatile organic compounds ...
(Date:8/21/2014)... to ignore, but they are the ultimate source of ... are increasingly dependent on algae, too, to suck up ... to the bottom of the ocean. Now, by using ... have evidence showing that viruses infecting those algae are ... when all else stays essentially the same, and this ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Viruses take down massive algal blooms, with big implications for climate 2
... Human activities are degrading the Amazonian forest at twice ... adds the effects of logging to those of clear-cutting. ... the journal Science , published by AAAS, the ... measuring deforestation across large areas have only been capable ...
... effective vaccines for people with compromised immune systems ... team of researchers, who demonstrated their approach could ... same population of immune cells that HIV destroys ... Hospital of Pittsburgh researchers, working in collaboration with ...
... model systems for understanding fungal diseases, two groups of ... how carbon dioxide (CO2) governs the morphogenic changes that ... invade the human body, and they provide new evidence ... enzymes to control the growth and sexual reproduction of ...
Cached Biology News:Logging doubles threat to the Amazon, rivaling clear-cutting, study suggests 2New vaccine platform may fight infections with causes from influenza to bioterrorism 2New vaccine platform may fight infections with causes from influenza to bioterrorism 3CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3